We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows
Read MoreHide Full Article
On Nov 16, we issued an updated research report on Teleflex Incorporated (TFX - Free Report) . The company continues to report strong growth in UroLift. However, escalating costs and expenses remain a major cause of worry. The stock currently carries a Zacks Rank #3 (Hold).
Over the past six months, Teleflex’s stock has underperformed its industry. The stock has gained 3.2% compared with the industry's 17.5% growth.
In the third quarter, on a year-over year basis, earnings and sales both declined significantly. Most of the segments registered revenue decline organically on a 12% aggregated negative impact from COVID-19. Margin debacle is another major concern. Teleflex is currently unable to ascertain the scope and duration of the pandemic as well as quantify the actual impact.
The company also anticipates material disruption caused by the evolving COVID-19 pandemic and macroeconomic environment. It further expects significant adverse financial impact of the coronavirus pandemic. This time too the company has not provided its 2020 outlook.
On a positive note, in the third quarter, in terms of UroLift, the response to the company’s national DTC campaign exceeded expectations. Web traffic increased more than 150% since the launch and another encouraging metric is that multiple urologists are now motivated to get trained on UroLift as a result of patient requests due to the campaign.
In terms of UroLift 2, since the FDA clearance on Jul 31, the company has begun a market acceptance test and received positive preliminary feedback, including the streamlining of the delivery device triggering mechanism and the reduction of waste. Teleflex is currently increasing manufacturing levels for the product ahead of the full commercial launch slated for early 2021. Regarding the UroLift ATC, the market acceptance test is well underway.
In the third quarter, the Vascular Access segment reported 6.8% growth on robust performances of PICC and EZ-IO products. COVID-19 positively impacted the growth rates of vascular products during the third quarter by approximately 1%.
Over the past six months, Teleflex’s stock has underperformed its industry. The stock has gained 2.5% compared with the industry's 15.5% growth.
Stocks to Consider
Some better-ranked stocks from the broader medical space are ResMed (RMD - Free Report) , Thermo Fisher Scientific (TMO - Free Report) and Align Technology (ALGN - Free Report) .
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2.
Align Technology’s long-term earnings growth rate is estimated at 18.3%. It currently carries a Zacks Rank #2.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows
On Nov 16, we issued an updated research report on Teleflex Incorporated (TFX - Free Report) . The company continues to report strong growth in UroLift. However, escalating costs and expenses remain a major cause of worry. The stock currently carries a Zacks Rank #3 (Hold).
Over the past six months, Teleflex’s stock has underperformed its industry. The stock has gained 3.2% compared with the industry's 17.5% growth.
In the third quarter, on a year-over year basis, earnings and sales both declined significantly. Most of the segments registered revenue decline organically on a 12% aggregated negative impact from COVID-19. Margin debacle is another major concern. Teleflex is currently unable to ascertain the scope and duration of the pandemic as well as quantify the actual impact.
Teleflex Incorporated Price
Teleflex Incorporated price | Teleflex Incorporated Quote
The company also anticipates material disruption caused by the evolving COVID-19 pandemic and macroeconomic environment. It further expects significant adverse financial impact of the coronavirus pandemic. This time too the company has not provided its 2020 outlook.
On a positive note, in the third quarter, in terms of UroLift, the response to the company’s national DTC campaign exceeded expectations. Web traffic increased more than 150% since the launch and another encouraging metric is that multiple urologists are now motivated to get trained on UroLift as a result of patient requests due to the campaign.
In terms of UroLift 2, since the FDA clearance on Jul 31, the company has begun a market acceptance test and received positive preliminary feedback, including the streamlining of the delivery device triggering mechanism and the reduction of waste. Teleflex is currently increasing manufacturing levels for the product ahead of the full commercial launch slated for early 2021. Regarding the UroLift ATC, the market acceptance test is well underway.
In the third quarter, the Vascular Access segment reported 6.8% growth on robust performances of PICC and EZ-IO products. COVID-19 positively impacted the growth rates of vascular products during the third quarter by approximately 1%.
Over the past six months, Teleflex’s stock has underperformed its industry. The stock has gained 2.5% compared with the industry's 15.5% growth.
Stocks to Consider
Some better-ranked stocks from the broader medical space are ResMed (RMD - Free Report) , Thermo Fisher Scientific (TMO - Free Report) and Align Technology (ALGN - Free Report) .
ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2.
Align Technology’s long-term earnings growth rate is estimated at 18.3%. It currently carries a Zacks Rank #2.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>